InfinityRx selects AshHEALTH to advance its proprietary patient service platform
AshHEALTH, a Rochester, N.Y. healthcare advisory and market development firm, has inked a deal to represent InfinityRx, a New York-based company that developed a patient affordability platform for patient service programs. AshHEALTH will assume the InfinityRx go-to-market, commercialization and capitol venture strategy.
InfinityRx recently launched its proprietary PSP platform in addressing some of the most important dynamics impacting co-pay assistance programs. Co-founded by two veteran New York pharmacists, the company boasts a cloud-based platform that offers a unique and easy-to-administer digital method for brand pharmaceutical drug manufacturers to buy-down expensive prescription medication.
The InfinityRx platform delivers a flexible, mobile and innovative rules engine that electronically drives a targeted price discount or co-pay assistance to high-cost medications at the POS retail level and all sites of care for treatment. A manufacturer can customize its target price and program benefits directly into the InfinityRx signature proprietary platform and make changes that become effective and fully operational for patients to experience the benefit in real-time, under 24-hours versus historical platforms that can take up to thirty days to deploy, the company noted.
[Read more: Leveraging robotics to increase pharmacists' time for clinical services]
The company's platform enables prescription drug manufacturers to help patients avoid prescription drug abandonment, and to reduce medication nonadherence, which for years has been reported as a nationwide pandemic, the company said.
AshHEALTH applies a stringent rubric to qualifying the companies it selects to represent. According to its founder, a successful healthcare industry executive with nearly 25 years of industry experience dedicated to building and managing successful start-ups, AshHEALTH undergoes a strict analysis and review of each company it chooses to adopt into its diverse client portfolio.
"A company must pass three factors. First, the management team and founders need to reflect competence and passion. Second, a marketable product is essential and must reveal an identity. Third, the product and service model are engineered to support a niche market while proving innovative and inventive to its buyer," said Ashton Maaraba, founder and CEO of AshHEALTH.
[Read more: DSN webinar explores how pharmacists can navigate test to treat to treat programs]
Maaraba continued, "InfinityRx checked off all the boxes and leads its portfolio as an exemplary next-generation start-up for patient co-pay assistance and claims processing platforms.
"InfinityRx was founded with the mindset that change and innovation in this product field is essential," said Greg Savino, CEO of InfinityRx. "Patients rely on timely subsidies and manufacturers deserve a new solution that is robust and flexible to suit their needs. Our team of pharmacy experts, software engineers and architects witnessed firsthand the shortcomings of the technology and solutions provided by traditional patient service programs. They are inflexible and inefficient, and this impacts pharma's ability to support patient needs in a timely and cost-effective fashion."
Savino added, "The InfinityRx patent approved technology and its advanced solutions solve this problem. AshHEALTH has a proven track record and provides us deep insight, industry knowledge and important connections that we find advantageous and beneficial to our company's comprehensive mission."